Antibody molecule targeting syndecan-1 for use in the treatment of multiple myeloma and plasmacytoma

The antibody molecule AT801 addresses the limitations of existing treatments by targeting a specific region of CD138, enhancing therapeutic efficacy and reducing tumor growth by inducing apoptotic death and immune-mediated responses, while minimizing off-target effects.

WO2026234583A1PCT designated stage Publication Date: 2026-11-12CENT DI RIFERIMENTO ONCOLOGICO DI AVIANO +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2026/054472
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-06
Filing Date
2026-05-06
Publication Date
2026-11-12

Smart Images

  • Figure IMGF000010_0001
    Figure IMGF000010_0001
  • Figure IMGF000015_0001_TABLE
    Figure IMGF000015_0001_TABLE
  • Figure IMGF000015_0002_TABLE
    Figure IMGF000015_0002_TABLE
Patent Text Reader

Abstract

Antibody molecule targeting Syndecan-1 for use in the treatment of multiple myeloma and plasmacytoma The invention pertains to an anti-CD138 antibody molecule capable of binding CD138. The antibody molecule may be conjugated to a cytotoxic agent to form an antibody-drug conjugate or conjugated to a nanoparticle bearing a therapeutic agent. The disclosure also provides isolated nucleic acid molecules encoding the antibody molecule of the invention, as well as a host cell that expresses the antibody molecule. The antibody molecule is also provided for use as a medicament, for the therapeutic treatment of tumors and for tumor diagnosis, as well as for use in an in vitro method for detecting CD138-expressing cells in a biological sample.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Antibody molecule targeting Syndecan-1 for use in the treatment of multiple myeloma and plasmacytoma

[0002] Field of the invention

[0003] The present disclosure pertains to biotechnology, specifically focusing on antibody-based therapies that target a tumor-associated antigen for the treatment of tumour diseases, including multiple myeloma and plasmacytoma.

[0004] Background of the invention

[0005] The field of targeted cancer therapy has rapidly evolved over the past several decades, fostering a landscape in which antibody-based interventions have become central to the treatment and diagnosis of malignancies. In this arena, antibodies designed to bind to characteristic cell surface antigens offer an avenue for both specific targeting of malignant cells and the delivery of therapeutic agents.

[0006] Syndecan-1, also known as CD138, is one such "tumor-associated antigen" (TAA) which is of interest as a target for targeted therapies and early diagnosis through the use of antibody-directed approaches.

[0007] Syndecan-1, also known as CD138, represents a molecular target that offers great opportunities for the treatment of various tumors in which it is over-expressed. CD138 is a proteoglycan consisting of 310 amino acids expressed on the cell surface. It consists of an extracellular N-terminal region and an intracellular C-terminal region1. Syndecan-1 extracellular domain has five sites where glycosaminoglycan (GAG) chains can be attached. Two are located close to the plasma membrane and three are toward the N-terminus. The GAG chains added to CD138 are of two types: heparan sulfate and / or chondroitin sulfate; the latest is located exclusively near the plasma membrane, whereas one or more heparan sulfate chains are always located at its N-terminus2. Functionally, syndecan-1 plays a crucial role in mediating cell adhesion by interacting with extracellular matrix proteins, modulating cell signaling pathways, and participating in the regulation of immune responses. Widelyrecognized as a distinctive marker of plasma cells3, CD 138 represents a standard diagnostic biomarker in multiple myeloma4; however, its expression is not confined to this cell type. It is found in epithelial cells, fibroblasts, and endothelial cells, indicating its diverse cellular distribution and its different expression pattern is related to different malignancies: pancreatic5and breast cancer6are related to a high expression, whereas low cell surface syndecan-1 level is associated with a poor prognosis in lung, head, and neck7and in colorectal cancer8,9and renal carcinomas10.

[0008] A remarkable feature of syndecan-1 shedding involves the proteolytic cleavage of its extracellular domain, resulting in the release of soluble syndecan-1 fragments into the extracellular environment. This shedding event has been linked to diverse cellular functions, including the regulation of cell adhesion, migration, and inflammation11.

[0009] The general approach of harnessing TAAs has underpinned numerous therapeutic and diagnostic strategies, with ongoing research focused on enhancing their selectivity and therapeutic index.

[0010] Contemporary therapeutic strategies strive to couple high target specificity with potent antitumor activity, thereby addressing the challenges posed by complex diseases. Current treatments have been designed to selectively engage tumor cells with minimal impact on healthy tissues. In practice, this involves not only the use of antibodies to recognize malignancy-associated antigens but also the integration of therapeutic payloads that aid in the direct elimination of cancer cells. Such approaches are continually refined as clinicians and researchers work toward improved modalities that combine diagnostic precision with therapeutic efficacy, particularly for conditions where existing interventions fall short of achieving long-term control.

[0011] Many existing treatment approaches, though innovative, still encounter significant challenges in achieving optimal clinical outcomes. Conventional methods that target cell surface markers on malignant cells can sometimes suffer from limitations in cell-killing efficiency and may be hindered by mechanisms that undermine sustained therapeutic activity. Additionally, variability in antigen expression among diseased cells cancompromise the consistency of the therapeutic response. These challenges underscore the pressing need for continued innovation in the field, aiming to design more refined methodologies that can effectively target malignant cells while overcoming limitations associated with conventional evaluative strategies.

[0012] A specific challenge lies in addressing the multifaceted nature of tumor biology, particularly concerning aspects of cell adhesion, migration, and dissemination that contribute to disease progression. Existing modalities often focus on direct cytotoxic effects or on facilitating immune-mediated clearance, yet may not fully counteract the dynamic processes that allow malignant cells to evade treatment and spread. As a result, there remains a need for more precise therapeutic strategies that not only diminish tumor cell viability but also disrupt the complex interactions that underpin tumor growth and metastasis. This underscores an ongoing demand for improved platforms that can achieve a balance between potent antitumor activity and enhanced selectivity, leading to more effective treatment outcomes.

[0013] J-M Dore et al., FEBS Letters 426 (1998) 67-70 describes the characterization of the syndecan-1 epitopes for the monoclonal antibodies B-B2 and B-B4 using a phage display peptide library. B-B4 specifically recognizes a linear epitope on syndecan-1 (CD138) between residues 90 and 93 of the mature protein. B-B4 is noted for its ability to specifically identify human plasma cells among hematopoietic cells. The document suggests that B-B4 can be used to isolate pure populations of myeloma cells from bone marrow samples, indicating its utility in research and potentially in clinical diagnostics.

[0014] P. Tassone et al., BLOOD, 1 DECEMBER 2004 -Vol. 104, no.12, pages 3688-3696 discuss the development and testing of an antibody-drug conjugate (ADC) composed of the B-B4 antibody linked to the cytotoxic agent maytansinoid (DM1). The conjugate, B-B4-DM1, is designed to target CD138-expressing multiple myeloma cells. The B-B4-DM1 conjugate demonstrates selective cytotoxicity against CD138+multiple myeloma cell lines and patient cells in vitro. The conjugate also shows antitumor activity in vivo in several mouse models, including SCID mice with human multiple myeloma xenografts. The ADC works by binding to CD 138 on the surface of myeloma cells, leading to internalization and release of the cytotoxic agent DM1, which inhibits tubulin polymerization and induces cell death.However, the monoclonal antibody B-B4 is not able to induce direct apoptosis of CD138 positive cell lines12nor to interact with Fc-receptors on effector cells13; consequently, no therapeutic effect was documented in an animal model14

[0015] Antibody molecules which specifically bind to CD 138 and their uses in treating, preventing, and diagnosing disorders such as multiple myeloma are also disclosed in EP3692069 A.

[0016] F. Riccardi et al., Front. Oncol. 14:1370854. doi: 10.3389 / fonc.2024.1370854, provides a comprehensive review of therapeutic approaches targeting CD 138 in the context of multiple myeloma. It highlights CD138 (Syndecan-1) as a significant target due to its high expression on malignant plasma cells and its role in tumorigenesis and progression. The document discusses various strategies, including monoclonal antibodies and antibody-drug conjugates (ADCs), that exploit CD138 overexpression to deliver targeted treatments. Monoclonal antibodies like B-B4 are mentioned for their therapeutic potential, particularly in ADCs designed to selectively kill myeloma cells. The reference also covers ongoing clinical trials and preclinical studies showing promising results in tumor regression and improved survival rates. Challenges such as off-target effects and variability in CD138 expression are acknowledged, emphasizing the need for further research to optimize these therapies.

[0017] Thus, overall, the prior art identified above discloses various therapeutic strategies targeting CD138, such as monoclonal antibodies and antibody-drug conjugates (ADCs). While effective, these approaches can result in off-target effects and variability in efficacy due to differences in CD138 expression among patients. Additionally, the development of resistance mechanisms by cancer cells further complicates treatment, reducing the long-term effectiveness of these therapies. ADCs targeting CD138, such as indatuximab ravtansine (BT062), have shown promise in preclinical models, but challenges remain in optimizing drug delivery and minimizing damage to healthy tissues.

[0018] Summary of the invention

[0019] In order to overcome these and other drawbacks of the prior art, the present inventionprovides an antibody molecule designated as “AT801”, which is designed to target a specific region of syndecan-1 (CD138) involved in important cellular interactions, such as cleavage and binding with VEGFR2 and VLA-4.

[0020] The present inventors obtained the antibody molecule AT801 by immunization of mice with a nucleotide sequence encoding for a 160 amino acid (AA) long peptide of the syndecan-1 (CD 138) C-terminal region. This peptide includes the amino acid involved in the cleavage and subsequent shedding of CD138 (cleavage at position 242-243) as well as in the interaction of shaded CD 138 with VEGFR2 and VLA-4 (region 210-236). This targeted approach aims to reduce tumor cell adhesion and migration, potentially overcoming resistance mechanisms and enhancing therapeutic efficacy. AT801 induces direct cytotoxic effects on cancer cells, enhances immune-mediated responses, and facilitates the delivery of cytotoxic agents through ADCs. By focusing on a distinct mechanism of action, AT801 offers a novel approach to improving outcomes for patients with CD138-expressing tumors, such as multiple myeloma and plasmacytoma, providing a more precise and effective targeting strategy.

[0021] As it will be shown in the experimental section of the present disclosure, AT801 exhibits several advantageous characteristics, including the ability to specifically recognize CD 138 in vitro and in vivo, induce apoptotic death of CD 138-positive cancer cells, mediate Fc-dependent immunotherapy, selectively direct cytotoxic drug in CD 138-positive cancer cells, recognize the CD138 protein in vivo, and reduce CD138-expressing tumor masses in vivo.

[0022] AT801 can be utilized in various therapeutic approaches, such as monoclonal antibody therapy, antibody-drug conjugates (ADCs), and nanoparticle -based drug delivery systems.

[0023] AT801 has been provided as an IgG monoclonal antibody or in the form of a single-chain variable fragments (scFv). A single-chain antibody fragment (scFv) may be used for the development of chimeric antigen receptor (CAR) constructs, enabling the production of CAR-T or CAR-NK cells targeting CD138-expressing tumors.

[0024] The invention also encompasses diagnostic applications, wherein AT801 is used to detectCD138-expressing cells in vivo or in biological samples, providing a basis for accurate tumour diagnosis and monitoring of tumor progression.

[0025] Detailed description of the invention

[0026] The invention will now be described in more detail. The appended independent and dependent claims form an integral part of the detailed description which follows.

[0027] A first aspect of the present invention is an anti-CD138 antibody molecule, wherein said antibody molecule comprises:

[0028] - a heavy chain variable region which comprises three heavy chain complementaritydetermining regions (HCDR1, HCDR2 and HCDR3), wherein HCDR1 comprises the amino acid sequence of SEQ ID NO:4 (GYTFTDYS), HCDR2 comprises the amino acid sequence of SEQ ID NO:6 (INTETGEP), and HCDR3 comprises the amino acid sequence of SEQ ID NO: 8 (CAREGGYDYEGVYYGVDYW); and

[0029] - a light chain variable region which comprises three light chain complementaritydetermining regions (LCDR1, LCDR2 and LCDR3), wherein LCDR1 comprises the amino acid sequence of SEQ ID NO: 11 (SSVSY), LCDR2 comprises the amino acid sequence of SEQ ID NO: 13 (DTS), and LCDR3 comprises the amino acid sequence of SEQ ID NO: 15 (CQQWHSHPLTF).

[0030] In the following, the antibody molecule of the invention as defined above is designated for brevity “AT801”.

[0031] In a preferred embodiment of the antibody molecule AT801, the heavy chain variable region comprises or consists of the amino acid sequence of SEQ ID NO:2 and the light chain variable region comprises or consists of the amino acid sequence of SEQ ID NO:9.

[0032] The term “antibody molecule” is intended to include any protein which is produced by the immune system or which is an engineered fusion protein, such as a full length immunoglobulin or a single chain variable fragment (scvF), as long as it comprises at least a heavy chain variable region and a light chain variable region, wherein the heavy chainvariable region comprises at least three heavy chain complementarity-determining regions (HCDR1, HCDR2 and HCDR3) and the light chain variable region comprises at least three light chain complementarity-determining regions (LCDR1, LCDR2 and LCDR3).

[0033] In a preferred embodiment of the invention, AT801 is in the form of a full-length IgG antibody.

[0034] A full-length IgG antibody exhibits a Y-shaped structure composed of four polypeptide chains: two identical heavy chains and two identical light chains. Each heavy chain contains one variable domain (VH) at its N-terminus, which is crucial for antigen binding, followed by three constant domains (CHI, CH2, CH3) that define the antibody isotype and mediate immune effector functions. A flexible hinge region is located between the CHI and CH2 domains, providing flexibility for antigen binding. Each light chain contains one variable domain (VL) at its N-terminus, also contributing to antigen binding, and one constant domain (CL). These four polypeptide chains are interconnected through disulfide bonds; two link the heavy chains in the hinge region, and one connects each heavy chain to a light chain. The variable domains (VH and VL) at the tips of the antibody's arms together form two identical antigen-binding sites, with the specific amino acid sequences within these variable regions, especially in the complementarity-determining regions (CDRs), dictating the antibody's target specificity. The constant domains (CH2 and CH3) of the heavy chains in the antibody's stem form the Fc region, which interacts with effector molecules and immune cells, thereby mediating functions such as complement activation and antibody-dependent cell-mediated cytotoxicity (ADCC). The CHI and CL domains primarily serve to provide structural support to the antigen-binding arms, known as Fab regions.

[0035] As mentioned, the inventors found that AT801 is able to induce apoptotic death of CD 138-positive cancer cells and to mediate Fc-dependent immunotherapy. Consequently, AT801, especially in the form of an IgG antibody, is a therapeutic antibody capable per se of inducing antitumor effects.

[0036] Since the cytoplasmic domain of CD138 is associated with intracellular signaling pathways, its role contributes to signal transduction in different pathways. Specifically, syndecan-1exerts mainly its functions via the heparan sulfate chains, which ligate to a wide range of proteins, including heparin-binding growth factors and their corresponding receptors, i.e., Wnt15 16. Thus, functional neutralization of CD138 using the AT801 antibody molecule of the invention shall provide benefits both in terms of reducing tumor growth, metastasis, and angiogenesis, and in remodeling the tumor microenvironment, making it more susceptible to treatments and reducing the state of immunosuppression. The ability of AT801 to interact with immune system effector cells via Fc is also an important feature for an antibody-mediated therapy, as this interaction may elicit various types of immune responses, such as antibody-dependent cell cytotoxicity (ADCC), antibody-dependent cell phagocytosis (ADCP), activation of the complement system.

[0037] Another aspect of the invention is the antibody molecule AT801 as defined above conjugated to a cytotoxic agent to form an antibody-drug conjugate (ADC). Alternatively, the antibody molecule AT801 as defined above may be conjugated to a nanoparticle, usually through a linker arm, wherein the nanoparticle bears a therapeutic agent. By way of example, the therapeutic agent may be attached to the nanoparticle or it may be encapsulated within the nanoparticle.

[0038] Nanoparticle-based drug delivery platforms have emerged as suitable vehicles for overcoming pharmacokinetic limitations associated with conventional drug formulations. Nanoparticles have proven advantageous at solubilizing therapeutic cargo, substantially prolonging the circulation lifetimes of drugs. In the field of oncology, several therapies based on nanoparticles have been developed with properties tuned to improve drug delivery to the tumor, overcoming the impairments caused by chemotherapy and radiotherapy17. In addition, several nanoparticles have already been introduced into clinical practice, such as liposomal doxorubicin (Doxil) and nanoparticle albumin-bound paclitaxel (Abraxane)18 19. One of the most important applications of polymers in the biomedical field is the use of nanoparticles for drug delivery20. Polymeric nanoparticles offer several advantages: they are biodegradable, they allow controlled release of their cargo in a specific part of the body, they protect the drugs they contain from degradation and increase their solubility, they can be modified on the surface with specific molecules, they can be loaded with large amounts of drugs, they protect healthy tissues from the toxic effects of the anticancer drugs they contain,they offer excellent in-vitro and in-vivo stability, and they have an extended blood circulation time21'24

[0039] Among the different polymers commonly used to prepare polymeric nanoparticles are Poly(glycolic acid) (PGA), poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA). PGA, PLA, and PLGA are polymers from the polyester family. They were developed in the 1960s for surgical implants and tissue repair, but soon after, they were used for the controlled release of drugs25. They are biocompatible, non-toxic, and biodegradable due to hydrolytic cleavage at the ester bond between lactic acid and / or glycolic acid. These two subunits are endogenous substrates and are metabolized by the Krebs cycle in the cells26. In general, polymeric nanoparticles with a size between 200 and 300 nm can be easily prepared, an ideal size for a drug delivery approach, as they optimize internalization by tumor cells and increase retention time in the blood thanks to the effect of increased permeability and retention (EPR effect)27.

[0040] Regarding the conjugation of AT801 with nanoparticles, it should be emphasized that conventional chemotherapies are still used in clinical practice for the treatment of tumors despite the need to develop new and more effective therapies28. Very often, the lack of efficacy of these chemotherapeutic agents is due to the difficulty in reaching the tumor or the presence of resistance mechanisms in the tumor microenvironment. Another important problem is the possible occurrence of "off-side toxicity" phenomena29,30. In this context, conjugation of drug-loaded polymeric nanoparticles with the antibody targeting the TAA CD 138 may enhance the ability of the drug-loaded nanoparticles to reach the tumor site. Potential drugs loaded into polymeric nanoparticles conjugated with AT801 include doxorubicin (or other anthracyclines), or lenalidomide for the treatment of multiple myeloma or plasmacytoma.

[0041] Other chemotherapeutic agents commonly used for cancer treatment could also be loaded into polymeric nanoparticles to treat other specifically CD138-expressing tumors. As mentioned, CD138 is highly overexpressed in various solid tumors and hematological malignancies and represents one of the most specific target antigens for the identification of multiple myeloma (MM) cells. Accordingly, a further approach would be to use AT801conjugated to a cytotoxic agent31, such as emtansine or MMAE, two inhibitors of tubulin polymerization. In this way, the cytotoxic effect of emtansine or MMAE on healthy tissues (one of the main problems of conventional chemotherapies) shall be reduced and concentrated on the tumor, thanks to the possibility of specifically directing the cytotoxic drug to the CD138-expressing cancer cells targeted by AT80132.

[0042] Another aspect of the invention is the antibody molecule as defined above AT801 in the form of a single-chain variable fragment (scFv).

[0043] A single-chain variable fragment (scFv) is a fusion protein of the variable regions of the heavy (VH) and light chams(VL) of an bmrmnpglpbulin, either directly connected to each

[0044]

[0045] other or connected with a short linker peptide usually of 10 to about 25 am o aoids. This configuration allows the scFv to retain the antigen-binding specificity and affinity of the full antibody (as in a full length immunoglobulin, the antigen-binding regions in a scFv are determined by the CDRs located within the variable heavy (VH) and variable light (VL) chains) while being significantly smaller in size. The peptide linker may provide flexibility, enabling the VH and VL domains to properly orient for effective antigen binding.

[0046] The single-chain variable fragment (scFv) of the invention may be used for the development of chimeric antigen receptor (CAR) constructs, enabling the production of CAR-T or CAR-NK cells targeting CD138-expressing tumors. Adoptive cell therapy with chimeric antigen receptor (CAR) redirected T cells represents one of the most promising immunotherapeutic approaches.

[0047] At present, B cell maturation antigen (BCMA) is the most successful target used for CAR-T cell therapy in multiple myeloma, and anti-BCMA CAR-T cell therapy has achieved unprecedented responses in relapsing-remitting patients, even if with some limitations. Anti-BCMA CAR-T cell therapy exhibits short-term efficacy and many MM patients still experience disease recurrence or progression33. Consequently, there is a pressing need for continued innovation in the field of CAR-T cell therapy. Within this context, the heavy and light variable regions of AT801 are cloned to generate an anti-CD138 single-chain variable fragment (scFv); then, the sequence of the scFv is included in-frame in a CAR construct tocreate a CAR targeting CD138-expressing tumors; finally, immune cells (e.g. T cells or NK cells), usually taken from the patient to be treated, are engineered to express on their surface the CAR targeting CD138-expressing tumors.

[0048] Typically, a CAR comprises the following three domains: (i) an extracellular domain, designed to recognize a specific antigen present on the surface of the target tumor cells (in the present invention, the CD 138 antigen), (ii) a transmembrane domain usually consisting of a hydrophobic alpha helix that extends through the plasma membrane and that derives from a receptor membrane protein native to T lymphocytes, such as, for example, CD4, CD8, CD8a, CD3, CD3-zeta, CD28, 0X40 (CD134) or 4-1BB (CD137), and (iii) an intracellular domain responsible for lymphocyte activation signal transduction, able to signal within the cell the binding of the antigen recognition domain with its ligand, where said intracellular signalling domain derives for example from a protein selected from the group consisting of CD3zeta, FcRgamma, FcRbeta, FcRepsilon, CD3gamma, CD3delta, CD3epsilon, CD5, CD22, CD79a, CD79b and CD66d.

[0049] CARs with the above-illustrated structure are defined as first generation CARs. Despite a significant antigenic recognition ability, first generation CARs have shown limited antitumour activity. For this reason, further generations of CARs have been developed that have additional modifications, primarily at the intracellular domain level. In particular, second generation CARs are characterised by the insertion of a co- stimulation domain, for example a CD28 or 4 IBB domain, within the intracellular portion of the receptor. Third generation CARs, on the other hand, have been created by combining multiple co-stimulation domains within the endodomain, for example both CD28 domains or 4 IBB domains.

[0050] As illustrated above, the antibody molecule AT801 of the invention is suitable for use in therapeutic applications.

[0051] Accordingly, a further aspect of the invention is the antibody molecule AT801 as defined above for use as a medicament, preferably for use in the therapeutic treatment of a tumor disease, wherein the tumor is more preferably a CD138-expressing tumour. Particularly preferred examples of CD138-expressing tumors which may be effectively targeted by theantibody molecule AT801 of the invention are multiple myeloma and plasmacytoma.

[0052] The antibody molecule AT801 of the invention is also suitable for use in diagnostic applications, either in vivo or in vitro.

[0053] Accordingly, another aspect of the invention is the use of the antibody molecule AT801 as defined above for use in tumour diagnosis.

[0054] In this context, AT801 may be used e.g. as an imaging tool for in vivo tumour detection. MRI and PET tracers are routinely used to diagnose and monitor the progression of tumours such as multiple myeloma, however these tracers are far from optimal due to their nonspecific binding to tumor cells. Conjugation of the antibody molecule AT801 of the invention with a MRI or PET tracer, either directly or through a linker, may therefore significantly improve the imaging of tumor progression.

[0055] Furthermore, AT801 may be used in an in vitro method of detecting CD138-expressing cells in a biological sample, wherein the method comprises contacting the biological sample with AT801 and detecting the binding of AT801 to CD138-expressing cells in the biological sample, wherein the presence of bound AT801 is indicative of the presence of CD138-expressing cells in the biological sample.

[0056] EXPERIMENTAL SECTION

[0057] The following experimental section is provided by way of illustration only; it is not intended to limit the scope of the invention as defined by the appended claims.

[0058] The experimental section makes reference to the appended drawings, in which:

[0059] Figure 1 shows the results of the flow cytometry analysis of CD138 expression in different cell lines using AT801 or the commercial anti-CD138 antibody (Invitrogen, 38-2900).

[0060] Figure 2 shows representative immunofluorescence images of CD 138 protein in RPMI 8226 and Jurkat cell lines using AT801 and the commercial anti-CD138 antibody(Invitrogen, 38-2900) as a reference. Blue: nuclei; Red: membrane; Green: antibodies. Figure 3 shows the results of the experiments concerning the AT801 killing capability in-vitro. Apoptotic, Complement-Dependent Cytotoxicity, and Antibody-Dependent Cellular Phagocytosis activity of AT801 were evaluated in vitro and expressed as a percentage of viable cells.

[0061] Figure 4 shows the results of the experiments with an AT801 -derived antibody-drug conjugate (ADC); the ADC binds (A), is internalized in (B) and kill CD 138-positive cancer cells.

[0062] Figure 5 shows the results of experiments concerning in vivo AT801 biodistribution. Representative biodistribution of the AT801 (0.6 nmol Cy5.5, 60 pg AT801) and the IgG pool (Isotypic control), injected i.p. in a mouse model subcutaneously injected with RPMI 8226 cells. Whole-body scan of representative mice in a prone position is shown; fluorescence intensity images were acquired at the indicated time post-injection and are displayed in Radiant Efficiency. The circles in yellow enclose the tumor mass.

[0063] Figure 6 shows the results of experiments concerning in vivo AT801 biodistribution in tumor mass and liver. Data analysis of the biodistribution of the AT801 and the IgG pool (Isotypic control), injected i.p. in a mouse model subcutaneously injected with RPMI 8226 cells. Fluorescence intensity images were acquired every 24h and are displayed in efficiency. Data are reported as mean ± SEM (n=3). t-test: P < 0.05 = *; P < 0.01 = **.

[0064] Figure 7 shows the results of experiments concerning ex- vivo organs accumulation of AT801. Ex-vivo biodistribution of the AT801 (0.6 nmol Cy5.5, 60 pg AT801), compared with the IgG pool (Isotypic control), injected i.p. in a mouse model subcutaneously transplanted with RPMI 8226 cells. Fluorescence intensity images were acquired at 168 h and are displayed in efficiency (A) or as a percentage of signal (B). Data are reported as mean ± SEM (n=3). One-way ANOVA: P < 0.001 = ***.

[0065] Figure 8 shows the results of experiments concerning AT801 therapeutic effect in a subcutaneous model of RPMI 8226 cells. Tumor-bearing mice received i.p 5mg / kg of AT801 (green line) or the same amount of PBS (black line) until day 28. The experimental endpoint was set up at day 84. Data was visualized using Kaplan-Meier analysis. Log-rank test: P < 0.0001 = ****.

[0066] Figure 9 is a line graph that recapitulates the tumor growth trend. In black the control group (PBS) in green the group treated with the AT801. Data were represented as mean ±SEM. One-way ANOVA: P < 0.05 = *; P < 0.01 = **; P < 0.001 = ***; P < 0.0001 = ****.

[0067] Preparation of AT801

[0068] A nucleotide sequence corresponding to a 160 amino acid (AA) long peptide in the C-terminal region (from AA 151 to 310, of which 104 AA exposed outside the cell surface) of CD 138 was used to immunize mice, by using an in-vivo electroporation protocol, followed by serum titer and hybridoma formation.

[0069] In detail, the DNA sequence used for mice immunization encodes for:

[0070] CD138 (NP_001006947) last 160 AA SHPHRDMQPGHHETSTPAGPSQADLHTPHTEDGGPSATERAAEDGASSQLPAAEG SGEQDFTFETSGENTAVVAVEPDRRNQSPVDQGATGASQGLLDRKEVLGGVIAGG EVGEIFAVCEVGFMEYRMKKKDEGSYSEEEPKQANGGAYQKPTKQEEFYA (SEQ ID NO: 1)

[0071] This region of syndecan-1 includes the amino acid involved in the shedding of CD 138 (cleavage at position 242-243) and in the interaction of shedded CD138 with VEGFR2 and VLA-4 (region 210-236), a mechanism involved in the adhesion and migration of myeloma cells34. This is in order to increase the effectiveness of the developed antibody for the treatment of multiple myeloma affected patients by inhibiting the VEGFR2 / VLA4 binding exposition of a juxtamembrane site in CD138 / Syndecan-1, with the aim of reducing adhesion and migration of multiple myeloma cells.

[0072] Hybridoma cells were then obtained through a standard approach. AT801 in the form of an IgG was produced in cell supernatant and purified by affinity chromatography.

[0073] AT801 is characterized by the following sequences of the heavy chain and light chain variable regions:

[0074] IGHV sequence:

[0075] QIQLVQSGPELKKPGETVKISCKASGYTFTDYSMHWMKQAPGKGLKWMGWINTE TGEPTYAADFKGRFAFSLETSASTAYLQINNLKNADTATYFCAREGGYDYEGVYYGVDYW (SEQ ID N0:2)

[0076] IGHV sequence characterization:

[0077] Region Amino acid sequence SEQ ID NO: FR1 QIQLVQSGPEEKKPGETVKISCKAS 3

[0078] CDR1 GYTFTDYS 4

[0079] FR2 MHWMKQAPGKGLKWMGW 5

[0080] CDR2 INTETGEP 6

[0081] FR3 TYAADFKGRFAFSLETSASTAYEQINNLKNADTATYF 7

[0082] CDR3 CAREGGYDYEGVYYGVDYW 8

[0083]

[0084] IGLV sequence:

[0085] QIVLTQSPVIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKEAS GVPARFSGSGSGTSYSLTISSMEAEDAATYFCQQWHSHPLTF (SEQ ID N0:9) IGEV sequence characterization:

[0086] Region Amino acid sequence SEQ ID NO:

[0087] FR1 QIVLTQSPVIMSASPGEKVTMTCSAS 10

[0088] CDR1 SSVSY 11

[0089] FR2 MHWYQQKSGTSPKRWIY 12

[0090] CDR2 DTS 13

[0091] FR3 KEASGVPARFSGSGSGTSYSLTISSMEAEDAATYF 14

[0092] CDR3 CQQWHSHPETF 15

[0093]

[0094] Capability to specifically recognize the CD 138 protein in-vitro

[0095] a) AT801 has been shown to be capable of specifically recognizing the CD138 protein by flow cytometry in the CD138-expressing tumor cell line model RPMI 8226 cell (MultipleMyeloma tumor model). On the other hand, no signals corresponding to the presence of the CD 138 protein was obtained by performing flow cytometry experiments on the JURKAT cell line (T ALL model), characterized by the complete absence of the CD138 protein. Of note, the presence of CD 138 was studied by using a commercial anti-CD138 antibody (Invitrogen, 38-2900) in the same cell line models, confirming CD138 expression in RPMI 8226 cell line model and no expression of the CD 138 protein in the JURKAT (Figure 1).

[0096] b) AT801 has been shown to specifically recognize CD 138 protein by immunofluorescence in the CD138-expressing model cells of tumor cell line RPMI 8226. Remarkably, the same expression pattern as flow cytometry analysis was obtained by immunofluorescence in microscopy analysis using AT801. Notably, when immunofluorescence experiments were performed, a signal corresponding to the CD 138 protein was observed in the RPMI 8226 cell line, whereas, as expected, no signal was observed when the presence of the CD138 protein was examined in the JURKAT cells. These results are consistent with those observed using the commercial antibody (Invitrogen, 38-2900) used as a control (Figure 2). Thus, the results of immunofluorescence analysis confirmed the ability of AT801 to detect the CD138 protein observed when flow cytometry was performed.

[0097] Capability to induce apoptosis and Fc-mediated immunotherapy.

[0098] AT801 has been shown to be able to induce apoptosis and Fc-mediated immunotherapy in CD138+ RPMI 8226 cells. In-vitro apoptosis was evaluated by incubating target cells with AT801 or the commercial anti-CD138 antibody (as a control, Invitrogen, 38-2900) for 48h and then analyzing the residual percentage of living cells. This incubation resulted in a significant percentage of apoptotic cancer cell death caused by AT801 treatment (Figure 3).

[0099] Parallelly, the complement-dependent cytotoxicity was investigated by incubating AT801 or the commercial anti-CD138 antibody (as a control, Invitrogen, 38-2900) with a healthy donor’s serum (as a source of complement factors) and with the target RPMI 8226 cells for Ih. The residual percentage of living cells was evaluated, resulting in the absence of complement-dependent cytotoxicity caused by AT801, at least in vitro (Figure 3).Finally, the capacity of AT801 to interact with Fc-receptors on cell surface effector cells was investigated using the THP-1 cells differentiated into macrophages. Target RPMI 8226 cells, previously incubated with AT801 or the commercial anti-CD138 antibody (Invitrogen, 38-2900), were put in contact with macrophages. AT801, as well as the positive control, resulted in a high signal of target RPMI 8226 cells interacting with the macrophages (Figure 3); demonstrating the capacity of 801 to interact with Fc-receptor and to induce phagocytosis or ADCC of cancer cells.

[0100] Capability to selectively direct cytotoxic drug in CD 138-positive cancer cells

[0101] AT801 has been shown to be able to target and kill CD138-positive cells driving cytotoxic drugs into cancer cells as required in Antibody -Drug Conjugated and targeted nanoparticles approach. In particular, AT801 covalently bound to a drug, such as MMAE, and in the same way to a biodegradable polymeric particle as chitosan nanostructures, maintained the capacity to address CD138 positive cells (Figure 4A, orange bar) in a comparable manner than original AT801 (Figure 4A, blue bar) or commercial antiCD 138 antibody (Invitrogen, 38-2900). Moreover, after its binding, AT801 was internalized in cancer cells in a time dependent manner (Figure 4B), resulting in an effective killing of CD 138 positive cells at the dose of lOOOnm (Figure 4C).

[0102] Capability to recognize the CD 138 protein in-vivo.

[0103] AT801 has been shown to be able to target RPMI8226 tumor mass in xenograft mouse models obtained by subcutaneous injection ofRPMI8226 cells into SCID mice. Specifically, in vivo time course experiments with signal detection from 0 to 168 hours and signal evaluation every 24 hours were performed to evaluate the ability to target tumor mass and the overall biodistribution of AT801 when injected intraperitoneally, using the IVIS® Lumina III (PerkinElmer) in-vivo imaging system (Figure 5 and 6).

[0104] In these experiments, the accumulation of AT801 on the CD138+ RPMI 8226 tumor mass was assessed from the time point of 24 hours, and the signal was found to be maintained up to 168 hours, with a peak of accumulation at 96 hours. These results indicate that AT801 iscapable of reaching CD138+ tumor mass when injected in-vivo. Remarkably, a different distribution pattern was obtained when a pool of murine IgG was used as a control, with a more rapid peak of accumulation at 48 hours and a lower signal at 96 hours. A clear signal, corresponding to the presence of AT801 was also seen in the liver, as expected because this organ is responsible for body excretion (Figure 6).

[0105] Ex vivo analysis performed 168 hours after administration using the IVIS® Lumina III (PerkinElmer) in-vivo imaging system confirmed the in-vivo results with a higher accumulation of AT801 in the tumor mass compared to the IgG pool and the elimination through the liver (Figure 7).

[0106] Altogether, in vitro and in vivo data suggest that AT801 has the possibility to direct kill cancer cells by apoptosis and interacting with NK cells through ADCC while a low level of complement activation has been documented.

[0107] Capability to reduce CD138-expressing tumor masses in-vivo.

[0108] AT801 has been shown to be able to reduce tumor growth when used to treat RPMI8226 injected xenograft mouse models. This evidence has been demonstrated in an in-vivo experiment, in which the CD138-expressing RPMI8226 model was established in SCID mice and randomly divided in 2 groups. One group was intra-peritoneally treated with 5mg / kg of the AT801 once a week whereas the other group as treated once a week with PBS as a control. The treatment procedure started when the tumor reached a volume of 200 mm3 and continued for 5 weeks.

[0109] The final experimental endpoint was set up on day 84 from the beginning of the treatment procedure.

[0110] Survival time intervals of mice treated with the AT801 were significantly longer than those of mice treated with PBS (P<0.0001, log-rank test, Figure 8).

[0111] Moreover, the dimension of the tumor mass was measured three times a week with a caliperto assess the effect mediated by AT801 on tumor growth (Figure 9).

[0112] The treatment with the AT801 induced a significant reduction of tumor growth already after 2 weeks of treatment, prolong the survival of the animal, causing tumor cell death by apoptosis and ADCC, as demonstrated in vitro and ex vivo.

[0113] References

[0114] 1. Stepp MA, Pai-Ghosh S, Tadvalkar G, Pajoohesh-Ganji A. Syndecan-1 and Its Expanding List of Contacts. Adv Wound Care (New Rochelle). Apr 1 2015;4(4):235-249. doi: 10.1089 / wound.2014.0555

[0115] 2. Langford JK, Stanley MJ, Cao D, Sanderson RD. Multiple heparan sulfate chains are required for optimal syndecan-1 function. J Biol Chem. Nov 6 1998;273(45):29965-71. doi: 10.1074 / jbc.273.45.29965

[0116] 3. Hosen N, Matsuoka Y, Kishida S, et al. CD 138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. Leukemia. Sep 2012;26(9):2135-41. doi:10.1038 / leu.2012.80

[0117] 4. Ridley RC, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson RD. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood. Feb 1 1993;81(3):767-74.

[0118] 5. Conejo JR, Kleeff J, Koliopanos A, et al. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer. Oct 1 2000;88(l): 12-20. doi:10.1002 / 1097-0215(20001001)88:l<12::aid-ijc3>3.0.co;2-t

[0119] 6. Matsuda K, Maruyama H, Guo F, et al. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res. Jul 152001;61(14):5562-9.

[0120] 7. Anttonen A, Heikkila P, Kajanti M, Jalkanen M, Joensuu H. High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery. Lung Cancer. Jun 2001;32(3):297-305. doi:10.1016 / s0169-5002(00)00230-0

[0121] 8. Lundin M, Nordling S, Lundin J, Isola J, Wiksten JP, Haglund C. Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology. 2005;68(4-6):306-13. doi: 10.1159 / 000086969

[0122] 9. Mitselou A, Skoufi U, Tsimogiannis KE, et al. Association of syndecan-1 with angiogenesis-related markers, extracellular matrix components, and clinicopathological features in colorectal carcinoma. Anticancer Res. Sep 2012;32(9):3977-85.

[0123] 10. Gokden N, Greene GF, Bayer-Garner IB, Spencer HJ, Sanderson RD, Gokden M. Expression of CD138 (Syndecan-1) in renal cell carcinoma is reduced with increasing nuclear grade. Appl Immunohistochem Mol Morphol. Jun 2006;14(2): 173-7. doi:10.1097 / 01.pai.0000168592.58721.7d

[0124] 11. Szatmari T, Dobra K. The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumors. Front Oncol. Dec 19 2013;3:310. doi: 10.3389 / fonc.2013.00310

[0125] 12. Ramani VC, Purushothaman A, Stewart MD, et al. The heparanase / syndecan-1 axis in cancer: mechanisms and therapies. FEBS J. May 2013;280(10):2294-306. doi:10.1111 / febs.12168

[0126] 13. Weinhold N, Heuck CJ, Rosenthal A, et al. Clinical value of molecular subtyping multiple myeloma using gene expression profiling. Leukemia. Feb 2016;30(2):423-30. doi:10.1038 / leu.2015.309

[0127] 14. Masola V, Gambaro G, Tibaldi E, et al. Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells. J Biol Chem. Jan 62012;287(2): 1478-88. doi: 10.1074 / jbc.Ml 11.279836 15. Cruz E, Kayser V. Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biologies. 2019;13:33-51. doi:10.2147 / BTT.S166310

[0128] 16. Dong S, Ghobrial IM. Immunotherapy for hematological malignancies. J Life Sci (Westlake Village). Jun 2019;l(l):46-52.

[0129] 17. Shah A, Rauth S, Aithal A, et al. The Current Landscape of Antibody -based Therapies in Solid Malignancies. Theranostics. 2021 ; 11(3): 1493-1512. doi: 10.7150 / thno.52614 18. Janne PA, Johnson BE. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res. Jul 15 2006;12(14 Pt 2):4416s-4420s. doi: 10.1158 / 1078-0432.CCR-06-0555

[0130] 19. Kansara RR, Speziali C. Immunotherapy in hematologic malignancies. Curr Oncol.Apr 2020;27(Suppl 2):S 124-S 131. doi: 10.3747 / co.27.5117

[0131] 20. Alexander CM, Reichsman F, Hinkes MT, et al. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet. Jul 2000;25(3):329-32. doi: 10.1038 / 77108

[0132] 21. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. Apr 2000;6(4):443-6. doi: 10.1038 / 74704 22. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. Dec 2 2005;310(5753): 1510-2. doi: 10.1126 / science.1118948

[0133] 23. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. May 2010; 10(5):317-27. doi:10.1038 / nri2744

[0134] 24. Beauvais DM, Rapraeger AC. Syndecan-1 -mediated cell spreading requires signaling by alphavbeta3 integrins in human breast carcinoma cells. Exp Cell Res. Jun 10 2003;286(2):219-32. doi:10.1016 / s0014-4827(03)00126-5

[0135] 25. Riccardi F, Tangredi C, Dal Bo M, Toffoli G. Targeted therapy for multiple myeloma: an overview on CD138-based strategies. Front Oncol. 2024;14: 1370854. doi: 10.3389 / fonc.2024.1370854

[0136] 26. Dore JM, Morard F, Vita N, Wijdenes J. Identification and location on syndecan-1 core protein of the epitopes of B-B2 and B-B4 monoclonal antibodies. FEBS Eett. Apr 10 1998;426(l):67-70. doi:10.1016 / s0014-5793(98)00310-x

[0137] 27. Tassone P, Goldmacher VS, Neri P, et al. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood. Dec 1 2004;104(12):3688-96. doi:10.1182 / blood-2004-03-0963

[0138] 28. von Strandmann EP, Hansen HP, Reiners KS, et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood. 2006; 107(5): 1955-1962. doi:10.1182 / blood-2005-05-2177 29. Navya PN, Kaphle A, Srinivas SP, Bhargava SK, Rotello VM, Daima HK. Current trends and challenges in cancer management and therapy using designer nanomaterials. Nano Converg. Jul 152019;6(l):23. doi: 10.1186 / s40580-019-0193-2

[0139] 30. Zhao CY, Cheng R, Yang Z, Tian ZM. Nanotechnology for Cancer Therapy Based on Chemotherapy. Molecules. Apr 42018;23(4)doi:10.3390 / molecules2304082631. Mabrouk M, Das DB, Salem ZA, Beherei HH. Nanomaterials for Biomedical Applications: Production, Characterisations, Recent Trends and Difficulties. Molecules. Feb 182021 ;26(4)doi:10.3390 / molecules26041077

[0140] 32. Bozzer S, Dal Bo M, Grimaldi MC, Toffoli G, Macor P. Nanocarriers as a Delivery Platform for Anticancer Treatment: Biological Limits and Perspectives in B-Cell Malignancies. Pharmaceutics. Sep 172022; 14(9)doi:10.3390 / pharmaceutics 14091965 33. Danhier F. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release. Dec 282016;244(Pt A): 108-121. doi: 10.1016 / j.jconrel.2016.11.015

[0141] 34. Bozzer S, Bo MD, Toffoli G, Macor P, Capolla S. Nanoparticles-Based Oligonucleotides Delivery in Cancer: Role of Zebrafish as Animal Model. Pharmaceutics. Jul 21 2021;13(8)doi:10.3390 / pharmaceuticsl3081106

Claims

CLAIMS1. An anti-CD138 antibody molecule, wherein said antibody molecule comprises:- a heavy chain variable region which comprises three heavy chain complementaritydetermining regions (HCDR1, HCDR2 and HCDR3), wherein HCDR1 comprises the amino acid sequence of SEQ ID NO:4 (GYTFTDYS), HCDR2 comprises the amino acid sequence of SEQ ID NO:6 (INTETGEP), and HCDR3 comprises the amino acid sequence of SEQ ID NO: 8 (CAREGGYDYEGVYYGVDYW); and- a light chain variable region which comprises three light chain complementaritydetermining regions (LCDR1, LCDR2 and LCDR3), wherein LCDR1 comprises the amino acid sequence of SEQ ID NO: 11 (SSVSY), LCDR2 comprises the amino acid sequence of SEQ ID NO: 13 (DTS), and LCDR3 comprises the amino acid sequence of SEQ ID NO: 15 (CQQWHSHPLTF).

2. The anti-CD138 antibody molecule of claim 1, wherein the heavy chain variable region comprises or consists of the amino acid sequence of SEQ ID NO:2 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:9.

3. The anti-CD138 antibody molecule of claim 1 or 2, wherein the antibody molecule is an IgG immunoglobulin.

4. The anti-CD138 antibody molecule according to any one of claims 1 to 3, wherein the antibody molecule is conjugated to a cytotoxic agent to form an antibody-drug conjugate (ADC).

5. The anti-CD138 antibody molecule according to any one of claims 1 to 3, wherein the antibody molecule is conjugated to a nanoparticle comprising a therapeutic agent attached thereto or encapsulated therein.

6. The anti-CD138 antibody molecule of claim 1 or 2, wherein the antibody molecule is a single-chain variable fragment (scFv).

7. The anti-CD138 antibody molecule of claim 6, wherein the single-chain variable fragment (scFv) is in the form of a soluble molecule or a transmembrane molecule.

8. An isolated nucleic acid molecule encoding an antibody molecule according to any one of claims 1 to 3 or 6 to 7.

9. A host cell expressing an antibody molecule according to any one of claims 1 to 3 or 6 to 7.

10. An antibody molecule according to any one of claims 1 to 7 for use in the therapeutic treatment of a tumour.

11. The antibody molecule for use according to claim 10, wherein the tumour is a CD138-expressing tumour.

12. The antibody molecule for use according to claim 11, wherein the tumour is multiple myeloma or plasmacytoma.

13. An antibody molecule according to any one of claims 1 to 3 or 6 for use in tumour diagnosis.

14. An in vitro method of detecting CD138-expressing cells in a biological sample, the method comprising:- contacting the biological sample with an anti-CD138 antibody molecule according to any one of claims 1 to 3 or 6; and- detecting the binding of the anti-CD138 antibody to CD138-expressing cells in the biological sample, wherein the presence of bound anti-CD138 antibody is indicative of the presence of CD138-expressing cells in the biological sample.